Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

News > All

Total search results: 17246 | Ordered by Source (ascending)
next pagenext page 1 2 3 ... 171 172 173  next pagenext page

order ascendingorder descendingSource order ascendingorder descendingDate
Werum IT Solutions AG. (3/1/17). "Press Release: Werum America Reinforces Key Account Relations with Experienced Pharma Manufacturing Specialist". Lüneburg & Parsippany, NJ. 2017-03-01
Werum IT Solutions AG. (5/16/19). "Press Release: Jens Woehlbier Assigned as New CEO of Werum IT Solutions". Lüneburg. 2019-05-16
Werum IT Solutions AG. (5/2/16). "Press Release: Pharma Tech Firms Werum IT Solutions and Zenith Technologies Announce Global MES Partnership". Lüneburg. 2016-05-02
Werum IT Solutions AG. (8/13/14). "Press Release: UNIGEN, Japan: – MES for Complex Biopharmaceutical Production Implemented in Only Four Months with Werum's PAS-X Out of the Box". Lüneburg. 2014-08-13
WFB Wirtschaftsförderung Bremen GmbH. (11/11). "Pressemitteilung: Projekt des Monats. Wir stellen vor – Molzym-Synovial Test". 2011-11-01
White & Chase. (12/27/11). "Pressemitteilung: White & Chase berät Banken bei Refinanzierung von Qiagen". München. 2011-12-27
Wilex AG. (1/13/16). "Press Release: Wilex’s Partner Link Health Submits IND Application for Clinical Phase I with the uPA inhibitor Mesupron in China". Munich. 2016-01-13
Wilex AG. (1/18/12). "Press Release: Wilex Successfully Completed Phase I Study in Healthy Volunteers with the Oral MEK Inhibitor WX-554". Munich. 2012-01-18
Wilex AG. (1/25/17). "Press Release: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement". Munich. 2017-01-25
Wilex AG. (1/29/14). "Press Release: Wilex AG Plans Extensive Cost-cutting Measures. Focus on Contract Research and ADC Technology". Munich. 2014-01-29
Wilex AG. (1/9/12). "Press Release: Wilex AG Resolves Rights Issue Using Authorised Capital [Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)]". Munich. 2012-01-09
Wilex AG. (10/10/11). "Press Release: Wilex Inc. and ALPCO Diagnostics Sign Marketing and Distribution Agreement for North America". Munich & Salem, NH. 2011-10-10
Wilex AG. (10/10/13). "Press Release: Wilex Publishes 9-Months Financial Report 2013". Munich. 2013-10-10
Wilex AG. (10/11/12). "Press Release: Wilex AG Publishes 9-months Financial Report 2012". Munich. 2012-10-11
Wilex AG. (10/13/10). "Presentation 9-Month Financial Report 2010. 13 October 2010". Munich. 2010-10-13
Wilex AG. (10/13/10). "Press Release: Wilex Publishes 9-Month Financial Report 2010. Mandatory Offer from dievini Hopp BioTech Closed". Munich. 2010-10-13
Wilex AG. (10/13/11). "Press Release: Wilex Publishes 9-Month Financial Report 2011". Munich. 2011-10-13
Wilex AG. (10/13/16). "Press Release: Interim Management Statement on the First Nine Months of 2016". Munich. 2016-10-13
Wilex AG. (10/14/14). "Press Release: Wilex Subsidiary Heidelberg Pharma Extends Research Collaboration with Roche". Munich. 2014-10-14
Wilex AG. (10/15/11). "Press Release: Wilex Reports an Adjustment of the Goodwill of Heidelberg Pharma AG According to IFRS". Munich. 2011-10-15
Wilex AG. (10/15/14). "Press Release: Wilex Publishes 9-Month Financial Report". Munich. 2014-10-15
Wilex AG. (10/16/12). "Press Release: Wilex AG Announces Results of Phase III ARISER Study with Rencarex in Clear Cell Renal Cell Carcinom. Trial Did Not Meet Its Primary Endpoint of Median Disease-free Survival (DFS)". Munich. 2012-10-16
Wilex AG. (10/26/12). "Press Release: Letter to Shareholders". 2012-10-26
Wilex AG. (10/26/16). "Press Release: Wilex AG. Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC)". Munich. 2016-10-26
Wilex AG. (10/5/11). "Press Release: FDA Grants Fast Track Designation to Wilex’s Rencarex for the Adjuvant Therapy of Clear Cell Renal Carcinoma". Munich. 2011-10-05
Wilex AG. (10/9/17). "Press Release: Interim Management Statement for the First Nine Months of 2017". Munich. 2017-10-09
Wilex AG. (10/9/17). "Press Release: Wilex AG Announces Adjustment of Guidance [Ad-hoc release – Insider information pursuant to Article 17 MAR]". Ladenburg. 2017-10-09
Wilex AG. (11/17/10). "Press Release: Wilex Acquires Oncogene Science Assets from Siemens Healthcare Diagnostics. Strategic Addition to Wilex’s Leading IP Portfolion in CA IX and uPA – Commerical Business with Product Revenues in Companion Diagnostics". 2010-11-17
Wilex AG. (11/21/11). "Press Release: Wilex AG. ARISER Independent Data Monitoring Committee (IDMC) Recommends Conducting the Final Analysis of the Pivotal Phase III Trial with Rencarex". Munich. 2011-11-21
Wilex AG. (11/23/15). "Press Release: Wilex AG Unveils Financing Strategy for Further Development of ADC Technology and Adopts Capital Measures". Munich. 2015-11-23
Wilex AG. (11/23/15). "Press Release: Wilex Publishes 9-month Financial Report". Munich. 2015-11-23
Wilex AG. (11/3/10). "Press Release: Wilex AG Announces Acquisition of Heidelberg Pharma AG. Access to Novel Antibody Drug Conjugate Platform Technogy for Therapeutic Antibodies in Cancer Treatment". Munich. 2010-11-03
Wilex AG. (11/7/13). "Press Release: Wilex Regains US Rights for Rencarex from Prometheus". Munich. 2013-11-07
Wilex AG. (12/12/12). "Press Release: Wilex Inc. Signs Distribution Agreement with Immundiagnostik AG for D-A-CH Region". Munich & Bensheim. 2012-12-12
Wilex AG. (12/17/10). "Press Release: Wilex AG Secures Further Financing with Shareholder Loans". Munich. 2010-12-17
Wilex AG. (12/4/12). "Press Release: Wilex AG Announces Restructuring". Munich. 2012-12-04
Wilex AG. (12/7/11). "Press Release: Wilex Inc. Lists Oncogene Science CA IX IHC Kit as an In-vitro Diagnostic with the FDA". Cambridge, MA & Munich. 2011-12-07
Wilex AG. (12/9/15). "Press Release: Wilex AG Successfully Completes Capital Increases". Munich. 2015-12-09
Wilex AG. (2/1/12). "Press Release: Wilex AG Successfully Completes Rights Issue (Ad-hoc release pursuant to $15 Wertpapierhandelsgesetz)". Munich. 2012-02-01
Wilex AG. (2/2/16). "Press Release: US Patent Office Granted Patent for Amatoxin Conjugates for Tumour Therapy". Munich. 2016-02-02
Wilex AG. (2/24/14). "Press Release: Professor Olaf G. Wilhelm Leaves the Executive Management Board on 31 March 2014, Dr Jan Schmidt-Brand Will Lead the Company". Munich. 2014-02-24
Wilex AG. (2/28/12). "Press Release: Wilex Reports on a Successful Financial Year 2011". Munich. 2012-02-28
Wilex AG. (2/6/12). "Press Release: Wilex Receives Funding from the German Federal Ministry of Education and Research for the Development of WX-037 as Part of the »m4 Cluster Initiative«". Munich. 2012-02-06
Wilex AG. (2/6/17). "Press Release: Wilex AG Secures Financing Commitment from Its Main Shareholder Dievini". Munich. 2017-02-06
Wilex AG. (3/20/13). "Press Release: Wilex Inc. and Nuclea Biotechnologies Inc. Announce Cooperation". Munich & Pittsfield. 2013-03-20
Wilex AG. (3/22/16). "Press Release: Wilex Announces Financial Figures for the 2015 Financial Year and Reports on Course of Business". Munich. 2016-03-22
Wilex AG. (3/26/15). "Press Release: Wilex Announces Financial Figures for the 2014 Financial Year and Reports on Course of Business". Munich. 2015-03-26
Wilex AG. (3/28/14). "Press Release: Wilex Enters into Licensing and Development Partnership for Mesupron in China with Link Health Group". Munich & Guangzhou. 2014-03-28
Wilex AG. (3/31/14). "Press Release: Wilex Announces Financial Figures for the 2013 Financial Year and Reports on Course of Business". Munich. 2014-03-31
Wilex AG. (4/10/14). "Press Release: Wilex AG Plans Reduction of Share Capital. Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)". Munich. 2014-04-10
Wilex AG. (4/12/12). "Press Release: Wilex Publishes Financial Report for the First Quarter of 2012. Rights Issue Successfully Concluded – Process for Final Analysis of Rencarex Started – Revenue and Earnings Improved". Munich. 2012-04-12
Wilex AG. (4/12/17). "Press Release: Interim Management Statement on the First Three Months of 2017". Munich. 2017-04-12
Wilex AG. (4/14/14). "Press Release: Wilex Published 3-Month Financial Reports 2014". Munich. 2014-04-14
Wilex AG. (4/24/17). "Press Release: Wilex AG Plans Rights Issue Using Authorised Capital. Ad-hoc release [Not for distribution, publication or transmission in the USA, Canada, Japan and Australia]". Munich. 2017-04-24
Wilex AG. (4/25/16). "Press Release: Wilex AG Successfully Completes Capital Increase". Munich. 2016-04-25
Wilex AG. (4/8/15). "Press Release: Wilex AG Successfully Completes Rights Issue". Munich. 2015-04-08
Wilex AG. (6/14/12). "Press Release: Mesupron Met Its Primary Objective of Demonstrating Efficacy in the Proof of Concept Phase II Breast Cancer Trial". Munich. 2012-06-14
Wilex AG. (6/19/17). "Press Release: Wilex Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates". Munich. 2017-06-19
Wilex AG. (6/2/16). "Press Release: Wilex AG Announces Change on the Executive Management Board". Munich. 2016-06-02
Wilex AG. (6/30/14). "Press Release: Wilex and RedHill Biopharma Enter into an Exclusive License Agreement for Mesupron". Munich & Tel Aviv. 2014-06-30
Wilex AG. (7/10/13). "Press Release: UCB Gets Access to Rights for an Antibody Programme from Wilex for Non-oncology Indications". Munich & Brussels. 2013-07-10
Wilex AG. (7/11/13). "Press Release: Wilex Publishes Half-yearly Financial Report 2013". Munich. 2013-07-11
Wilex AG. (7/12/12). "Press Release: Wilex Announces Results of Successful First Half Year 2012". Munich. 2012-07-12
Wilex AG. (7/13/17). "Press Release: Wilex Reports on First Half-year". Munich. 2017-07-13
Wilex AG. (7/14/15). "Press Release: Wilex Publishes Half-yearly Financial Report". Munich. 2015-07-14
Wilex AG. (7/15/14). "Press Release: Wilex AG Successfully Completes Capital Reduction. Reverse 4:1 Share Split Reduces Number of Outstanding Shares from 31.3 Million to 7.8 Million". Munich. 2014-07-15
Wilex AG. (7/15/14). "Press Release: Wilex Publishes Half-yearly Financial Report 2014". Munich. 2014-07-15
Wilex AG. (7/2/13). "Press Release: Burrill Securities Supports Wilex in Exploring Financing Partners". Munich. 2013-07-02
Wilex AG. (8/12/15). "Press Release: Wilex AG Announces Discontinuation of Collaboration between Its Subsidiary Heidelberg Pharma and Roche [Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)]". Munich. 2015-08-12
Wilex AG. (8/7/13). "Press Release: Wilex Starts Clinical Phase I Trial with PI3K Inhibitor WX-037". Munich. 2013-08-07
Wilex AG. (9/19/16). "Press Release: Wilex AG – Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center". Munich. 2016-09-19
Wilex AG. (9/2/13). "Press Release: Wilex Subsidiary Heidelberg Pharma Signs License Agreement for the Development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche". Munich. 2013-09-02
Wilex AG. (9/27/16). "Press Release: Subsidiary Heidelberg Pharma Contracts Suisse CDMO Celonic for Antibody Cell Line Development and Antibody Production". Munich. 2016-09-27
Wilex AG. (9/6/13). "Press Release: Nuclea Biotechnologies Inc. Acquires Wilex Inc. and Extends Their Cooperation with Wilex AG. Nuclea Purchased All Shares of Wilex Inc. (Oncogene Science)". Munich & Pittsfield, MA & Cambridge, MA. 2013-09-06
Wilson Therapeutics AB. (12/14/17). "Press Release: WTX101 Granted Fast Track Designation by the U.S. FDA for the Treatment of Wilson Disease". 2017-12-14
Wilson Therapeutics AB. (4/16/14). "Press Release: Wilson Therapeutics Secures $40 Million Private Financing to Advance Late Stage Development Program for Wilson’s Disease". Stockholm. 2014-04-16
Wise S.r.l.. (5/25/17). "Press Release: Wise Srl Raises EUR 6.5 Million for Clinical Validation of Novel Neuroelectrodes for Brain Monitoring and Spinal Cord Stimulation". Milan & Berlin. 2017-05-25
Wren Therapeutics Ltd.. (1/22/19). "Press Release: Wren Therapeutics Completes £18 Million Series A Financing". Cambridge. 2019-01-22
WuXi AppTec. (4/15/16). "Press Release: WuXi AppTec Acquires Crelux". Munich. 2016-04-15
WuXi NextCode. (9/7/17). "Press Release: WuXi NextCode Completes $240 Million Series B Financing". Shanghai, Cambridge, MA & Reykjavik. 2017-09-07
WuXi PharmaTech. (8/23/11). "Press Release: WuXi AppTec Bioanalytical Services Unit Receives GLP Certificate from OECD". Shanghai. 2011-08-23
Wyatt Technology Corporation. (1/22/14). "Press Release: Wyatt Technology to Launch the First SEC-MALS Detector for UHPLC at Pittcon". Santa Barbara, CA. 2014-01-22
Wyatt Technology Corporation. (11/16/10). "Press Release: Wyatt Technology Instrumentation Used against Bacteriophage Infections in Dairy Production". Santa Barbara, CA. 2010-11-16
Wyatt Technology Corporation. (6/24/11). "Press Release: Wyatt Technology MALS Fulfils Latest European Pharmacopoeia Standard for HES Characterization". Santa Barbara, CA. 2011-06-24
X-Biotix Therapeutics, Inc.. (7/1/19). "Press Release: X-Biotix Therapeutics Joins Antimicrobials Working Group". Washington, DC. 2019-07-01
Xceleron. (6/13/11). "Press Release: Xceleron Announces Key Board and Executive Appointments. Increasing Demand from Big Pharma for Greater R&D Productivity". York. 2011-06-13
Xeltis AG. (1/31/17). "Press Release: FDA Gives Xeltis Go Ahead to Begin Trials in the USA". 2017-01-31
Xeltis AG. (11/15/17). "Press Release: Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs". Zurich & Eindhoven. 2017-11-15
Xeltis AG. (12/17/15). "Press Release: Xeltis Extends Series B Financing to €30M, Signing off Transformational Year". Zurich. 2015-12-17
Xeltis AG. (2/2/16). "Press Release: Xeltis Appoints New CFO". 2016-02-02
Xeltis. (12/2/14). "Press Release: Xeltis Closes Euro 27 Million / USD 34 Million Series B Financing". Zürich. 2014-12-02
Xencor, Inc.. (1/7/19). "Press Release: Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody". Monrovia, CA. 2019-01-07
Xencor, Inc.. (2/5/19). "Press Release: Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech". Monrovia, CA. 2019-02-05
Xencor, Inc.. (4/4/12). "Press Release: Xencor Receives Second Milestone Payment from Boehringer Ingelheim under Antibody Technology License Agreement". Monrovia, CA. 2012-04-04
Xenetic Biosciences plc. (5/10/13). "Press Release: Commencement of Phase II with MyeloXen, the Novel Vaccine for Multiple Sclerosis". 2013-05-10
Xenikos B.V.. (5/15/18). "Press Release: Dutch Company Xenikos Secures USD 30 Million in Series B Financing". Nijmegen. 2018-05-15
Xenikos B.V.. (5/24/16). "Press Release: Xenikos B.V. to Introduce Immunotherapy T-Guard to Potential Pharmaceutical Partners at BIO International Convention 2016". Nijmegen. 2016-05-24
Xention Ltd.. (5/13/15). "Press Release: Xention Introduces Metrion Biosciences, a Specialist Ion Channel Screening Business". Cambridge. 2015-05-13
Xigen S.A.. (1/5/17). "Press Release: Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease". Geneva. 2017-01-05
XL-protein GmbH. (1/9/18). "Press Release: Horizon Pharma plc and XL-protein GmbH Have Entered Into a Collaboration Agreement on a Potential Next-Generation Biologic for Uncontrolled Gout Using PASylation® Technology". Freising. 2018-01-09
next pagenext page 1 2 3 ... 171 172 173  next pagenext page



Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [iito] Made Without Love 650x80px

» top